Calsyn Donald A, Malcy Jason A, Saxon Andrew J
Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA 98108, USA.
J Subst Abuse Treat. 2006 Mar;30(2):159-63. doi: 10.1016/j.jsat.2005.11.007.
Longitudinal studies have indicated that most opioid agonist-using patients are not able to successfully complete tapering attempts. Little is known, however, about tapering within a treatment environment that is supportive of indefinite agonist treatment and medication tapering. In this study, all records of patients beginning a slow methadone taper were reviewed (N = 30). No patient successfully completed methadone tapering. Four patients (13.3%) successfully switched to buprenorphine/naloxone, one of whom tapered off buprenorphine/naloxone. Three patients (10%) were continuing their taper at the study's end. One patient transferred to another program, one was administratively discharged, and one had his taper stopped for mishandling doses. The remaining patients (n = 20, 66.7%) stopped their tapers for the following reasons: feeling unstable/withdrawal symptoms (n = 4, 13.3%), drug use/positive urinalysis results (n = 12, 40%), psychiatric instability (n = 3, 10%), and pain management (n = 1, 3.3%). Only one patient prematurely left treatment secondary to a failed taper attempt. Patients attempting tapers should be informed about the difficulty involved and be monitored closely for signs of instability. For a few patients, a taper to a lower methadone dose and a switch to buprenorphine/naloxone are obtainable. Program policies that support both tapering attempts and indefinite maintenance are described in this article.
纵向研究表明,大多数使用阿片类激动剂的患者无法成功完成减药尝试。然而,对于在支持无限期激动剂治疗和药物减药的治疗环境中的减药情况,我们知之甚少。在本研究中,对开始缓慢美沙酮减药的患者的所有记录进行了回顾(N = 30)。没有患者成功完成美沙酮减药。四名患者(13.3%)成功转换为丁丙诺啡/纳洛酮,其中一名患者逐渐停用了丁丙诺啡/纳洛酮。三名患者(10%)在研究结束时仍在继续减药。一名患者转至另一个项目,一名患者被行政出院,一名患者因剂量处理不当而停止减药。其余患者(n = 20,66.7%)因以下原因停止减药:感觉不稳定/出现戒断症状(n = 4,13.3%)、药物使用/尿液分析结果呈阳性(n = 12,40%)、精神状态不稳定(n = 3,10%)以及疼痛管理(n = 1,3.3%)。只有一名患者因减药尝试失败而提前离开治疗。应告知尝试减药的患者其中涉及的困难,并密切监测其不稳定迹象。对于少数患者,可以实现减至较低剂量的美沙酮并转换为丁丙诺啡/纳洛酮。本文描述了支持减药尝试和无限期维持治疗的项目政策。